CFTR and lysozyme secretion in human airway epithelial cells.
Lysozyme is secreted in large quantities in human airways (10-20 mg/day), where it helps to defend against bacterial and fungal infection. Lysozyme expression is restricted to the serous cells of the submucosal glands, which also express high levels of cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels. It is often assumed that mucus secretion in human airways is coupled to anion secretion through CFTR Cl(-) channels located in the apical membrane. Therefore, a defect in CFTR function could cause abnormal mucus secretion leading to persistent bacterial infection and inflammation of the airways. In this study we measured simultaneous secretion of lysozyme and Cl(-) from human airway epithelial serous cells. Secretion of lysozyme was measured by a turbidimetric assay that relies on the ability of lysozyme to disrupt the wall of the bacterium Micrococcus lysodeikticus, thus causing a fall in the optical density of the sample. Secretion of Cl(-) was measured as short-circuit current in a modified Ussing chamber. Activation of Cl(-) secretion by stimulation of cAMP- or Ca(2+)-dependent pathways caused comparable increases in lysozyme secretion. Similarly, blockers of Cl(-) secretion, such as diphenylamine-2-carboxylate (DPC), also reduced lysozyme secretion. However, while treatment of airway submucosal gland cells with antisense oligonucleotides directed against CFTR reduced Cl(-) secretion, it had no significant effect on the total amount of lysozyme secretion. These results suggest a role for functional CFTR in regulation of lysozyme secretion in human airways.
Duszyk
M
M
Department of Physiology, University of Alberta, Edmonton, Alberta T6G 2H7, Canada. m.duszyk@ualberta.ca
D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid / Q000494:pharmacology; D001692:Biological Transport / Q000187:drug effects / Q000502:physiology; D002460:Cell Line; D002712:Chlorides / Q000378:metabolism; D005576:Colforsin / Q000494:pharmacology; D003550:Cystic Fibrosis / Q000378:metabolism; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D009113:Muramidase / Q000378:metabolism*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D020545:Respiratory Mucosa / Q000166:cytology / Q000201:enzymology* / Q000378:metabolism*; D026422:S-Nitrosoglutathione / Q000494:pharmacology; D019284:Thapsigargin / Q000494:pharmacology
C505032:CFTR protein, human; D002712:Chlorides; D004791:Enzyme Inhibitors; D020030:Nitric Oxide Donors; D016376:Oligonucleotides, Antisense; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D005576:Colforsin; D026422:S-Nitrosoglutathione; D019284:Thapsigargin; D009113:Muramidase; D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid